• Patient preference measured by a simple preference question.
  

• Better treatment adherence as measured by DAI-10
  
• Safety and tolerability as measured by AMDP-5
  
• Determine the predictors of drug compliance
  
• Mean change from baseline to endpoint in body mass index (BMI)
  
• Compare serum ghrelin levels
  
• Differences in subjective appetite from baseline to endpoint using a visual analog scale (VAS)
  
• Effect on the medication compliance, level of medication supervision, and willingness to remain on medication, as measured by Medication Adherence Form (MAF)
  
• Patient preference of the paranoid sub population as measured by a simple preference question
  

Inclusion Criteria:

• You are an outpatient diagnosed with stable schizophrenia.
• You are a male or female in the age of 18 to 65 years old.
• You are retrospectively judged by investigators, based on clinical interview and impression, to have been stable for at least 4 weeks.
• You must be able to take olanzapine orodispersible in a single daily dose.
• You are treated with conventional oral olanzapine tablet (as monotherapy) for at least 1 month.

Exclusion Criteria:

• You have used olanzapine in the past and are no longer using it because of a bad reaction.
• You have known Human immunodeficiency virus positive (HIV+) status.
• You have known uncorrected, narrow angle glaucoma.
• You have known Leukopenia, (abnormally low white blood cell count).
• You have a serious or uncontrolled illness (for example: liver disease, history of heart disease, or inadequately controlled diabetes.)
• You have Parkinson's disease.
• You are a female patient who is either pregnant or nursing
• You are taking medications that are not allowed in the study.